

CORPORATE HIGHLIGHTS



Alex Martin, CEO

“Our miniaturized MiFlow and PediaFlow systems are designed to be the next major advances in ventricular assist devices for adults and children.”

OFFICERS

John Alexander (Alex) Martin
President and CEO

Morgan Brown
EVP and CFO

John Campbell Woodard, MD
Chief Technology Officer

DIRECTORS

Michael S. Estes, PhD (Chairman)
Medical Entrepreneurs II

Jeani Delagardelle
New Leaf Venture Partners

William C. (Bill) Garriock
MDS Sciex, MDS Health Ventures

Anders D. Hove, MD
Venrock Associates

Eugene B. Jones (CPA)
KPMG, Bank of Utah

John Alexander (Alex) Martin
World Heart, Edwards Lifesciences

Austin W. Marxe
Special Situations Fund III

ANALYST COVERAGE

Duane Nash, MD, JD, MBA
Wedbush PacGrow Life Sciences


■ WorldHeart is developing the *MiFlow*™ VAD: a miniaturized ventricular assist device (VAD) slightly larger than a AA-battery that is designed to treat heart failure patients. VADs are mechanical devices that are surgically implanted to support a patient’s own heart by pumping a portion of the cardiac output.

■ WorldHeart believes that the tiny size of the *MiFlow* VAD will reduce the invasiveness of traditional VAD surgery and speed patient recovery. The small size is the result of using the Company’s breakthrough and proprietary Maglev™ technology. Because the *MiFlow* VAD represents a giant step in size reduction for VADs, the Company believes that the *MiFlow* VAD will support a larger patient population than just late-stage heart failure patients.

■ While the VAD market was \$350 million in 2010, it has the potential to expand to \$1 billion by 2015 (source: Canaccord Genuity). In addition to its miniature size, the *MiFlow* VAD is designed to have superior blood-handling characteristics than currently marketed VADs with respect to the reduction or elimination of acquired von Willebrand deficiency—believed to be a significant contributor to bleeding complications and hemorrhagic stroke. Consequently, WorldHeart expects to be a competitor in this developing market, as VADs expand to include *Bridge-to-Transplant* (BTT) therapy and *Destination Therapy* (DT).


■ WorldHeart’s second product development effort is the *PediaFlow*® VAD, which is intended for use in pediatric patients. Like the *MiFlow* VAD, the *PediaFlow* VAD is also expected to have improved blood-handling characteristics with respect to the reduction or elimination of acquired von Willebrand deficiency. *PediaFlow*’s development has been supported by two grants from the National Institutes of Health (NIH).

■ WorldHeart’s executive team is comprised of seasoned professionals, each with decades of experience in medical systems and devices. For example, WorldHeart’s CEO, Alex Martin, was previously President of the North American Region and Corporate VP at Edwards Lifesciences. (See full bios on website.)



MiFlow™ VAD

The *MiFlow* VAD is a minimally invasive VAD designed for Class IV and less severe (Class IIIb) heart failure patients.



PediaFlow® VAD

The *PediaFlow* VAD is a miniaturized, implantable VAD that is designed to be used in pediatric patients.